Sensus Healthcare, Inc.

Good afternoon and welcome to the Census Healthcare Third Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Kim Golodets with Alliance Advisors IR. Please go ahead.

Thank you. This is Kim Golodets with Alliance Advisors IR. Thank you all for participating in today's call. Joining me from Census Healthcare are Joe Sardano, Chairman and Chief Executive Officer, Michael Sardano, President and General Counsel, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities, census, health care, assumes, plans, expects, believes, intends, or anticipates, and other similar expressions, will, should, or may occur in the future, are forward-looking statements. The forward-looking statements are management's beliefs based on currently available information as of the date of this conference call, November 14th, 2024. Census Healthcare undertakes no obligation to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's forms 10-K and 10-Q. During today's call, references will be made to certain non-GAAP financial measures. Census believes these measures provide useful information for investors Yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's financial results press release. With that said, I'd like to turn the call over to Joe Sardano. Joe?

Thank you, Kim, and good afternoon, everyone. Before we jump into the meat of today's call, let me address the distribution of our earnings news release earlier today. As you know, we typically issue our financial announcements after the markets close. Today we had an accidental disclosure situation with the vendor that handles the distribution of our news releases. So out of an abundance of caution, we issued our third quarter news release and filed our 8K and 10Q during live trading hours. We expect to return to our normal timing cadence next quarter. And with that being said, I'm delighted to be reporting another quarter of continued growth in revenues and earnings. This reflects our success in engaging customers with both existing and new sales options for our SRT products. Revenues more than doubled year over year for the second consecutive quarter, and we maintained profitability despite the summer seasonality of our business. We shipped 27 SRT systems during the quarter, including one to Israel, as we continue to build a global presence. This compares with 11 systems shipped in the year-ago quarter. Once again, many of the shipments were for our SRT 100 vision systems, with guided SRT, including a higher number of such systems sold to a large, long-time customer. We value the business this customer provides and applaud their dedication to choosing a far more patient-friendly alternative to Mohs surgery with efficacy that's every bit as good. Our fair deal agreement, which we refer to as FDA, is proving to be as well-received as we had envisioned, perhaps even more so. The FDA is our new shared revenue IGSRT placement model, which we launched in March at the American Academy of Dermatology annual meeting. It complements our leasing programs as well as the outright sales of systems. During the third quarter, we signed seven FDA contracts for a total of 22 as of September 30th. And just this week, we entered into an exclusive agreement with Platinum Dermatology Partners, which will cover all their 130 clinical sites in the US. This is the largest sale to date under FDA or otherwise, and it holds potential to be a meaningful contributor to our top line. Platinum is a group dermatology practice with headquarters in Dallas. They have more than 400 clinicians, staffing clinics in Arizona, California, Florida, Nevada, and Texas. We expect to place several systems during the fourth quarter of 2024 and will continue to provide systems to the platinum network over time. Platinum has been a census customer for several years and has an unwavering commitment to patient care. We are delighted to enter into this collaboration to extend the benefits of superficial radiotherapy to even more patients with non-melanoma skin cancer and keloid scars. Non-melanoma skin cancer afflicts people nationwide. Platinum Dermatology's current geographic footprint makes for a particularly promising partnership as they aggressively pursue strategic expansion nationally. As a reminder, our fair deal agreement provides flexibility for the customers to deploy capital to other areas of their business. which is especially valuable under challenging macroeconomic conditions. Given the growing utilization of SRT to treat non-melanoma skin cancer and keloids and the interest we've generated to date, we believe this option will contribute to our growth for years to come. As our activities continue to grow, we fully expect our objectives for these agreements to be achieved by year end. All these agreements will begin to provide recurring revenue to Census beginning in 2025, with significant volumes projected for the second half of the year. And with that, I will ask Michael to discuss SRT expansion into the other strategic markets. Michael?